Table 2.
Baseline Characteristics by Treatment Arm in the A‐to‐Z Trial
| Characteristic | Placebo/Simvastatin 20 mg QD (n=2232) | Simvastatin 40 mg/80 mg QD (n=2265) |
|---|---|---|
| Age, y (mean±SD) | 60.6±10.5 | 60.2±10.9 |
| Male | 75.3% | 75.8% |
| White race | 84.7% | 85.4% |
| Diabetes mellitus | 23.8% | 23.4% |
| Hypertension | 49.6% | 50.0% |
| Serum creatinine (mean±SD, mg/dL) | 1.14±0.26 | 1.14±0.27 |
| eGFR (mean±SD, mL/min per 1.73 m2) | 60.1±19.5 | 60.3±19.8 |
| PCI for qualifying event | 43.9% | 43.2% |
| ACE‐I or ARB at hospital discharge | 75.7% | 74.2% |
| Baseline CKD stage (mL/min per 1.73 m2) | ||
| eGFR ≥90 | 9.3% | 8.6% |
| 60 to <90 | 29.2% | 30.8% |
| 30 to <60 | 60.0% | 58.8% |
| 15 to <30 | 1.6% | 1.8% |
| <15 | 0.05% | 0.09% |
ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention.